We are a specialist pan-European collective that comprises leading researchers in the field of diabetes and cancer.
Formed in 2011 by the then President of the European Association for the Study of Diabetes (EASD) Professor Ulf Smith, the Diabetes and Cancer Study Group (DCSG) is pooling new evidence and expertise to better understand the complex interplay between the two prolific disease areas of cancer and type 2 diabetes.
Our central objectives are:
- to establish minimum desirable criteria for the performance of descriptive studies in cancer epidemiology, survival, patient reported outcomes and pharmaco-epidemiology in relation to the field of diabetes;
- to create and implement a mechanism for pooling data and for conducting combined analyses inn relation to cancer and diabetes; and
- to undertake specific analyses in this area.
Our group is been tasked with investigating a series of controversial research findings, first published in 2009, that linked anti-diabetes therapies with an increased risk of cancer (read more here).
Following registration as a formal Study Group under the Presidency of Professor Andrew Boulton at 2013’s EASD Annual Conference, the core business of our Study group is the Diabetes and Cancer Research Consortium (DCRC (insert hyperlink)).
Our founding members – Ulf Smith (former EASD President); Edwin Gale (former editor-in-chief of Diabetologia); and Andrew Renehan (DCSG Chair) – are keen to retain visible affiliations with other related organisations such as European Cancer Organisation (ECCO) and the European Association for the Study of Obesity (EASO).